Eli Lilly to Build Largest AI Supercomputer in Pharma, Outpacing Recursion Pharmaceuticals
Eli Lilly has announced plans to build the largest AI supercomputer in the pharmaceutical industry, surpassing Recursion Pharmaceuticals, which currently operates the largest but has no market products or late-stage trials. Eli Lilly aims to leverage extensive data from past clinical trials to enhance its drug discovery process, positioning itself as a more stable investment compared to the high-risk profile of Recursion.
Theia Market Signal Identification - AI Assisted
Recursion Pharmaceuticals, a small-cap biotech company, operates the largest AI supercomputer in the pharmaceutical industry to accelerate drug development. Despite its innovative approach using a proprietary operating system and AI-powered algorithms to predict effective compounds for diseases, it has no products on the market or in phase 3 trials, making its stock high-risk. In contrast, Eli Lilly has announced plans to construct a larger AI supercomputer, leveraging extensive data from past clinical trials to enhance its drug discovery process, positioning it as a more stable investment compared to Recursion.
Comments